Aurobindo Pharma, today received the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Ramipril Capsules.
“Ramipril Capsules are indicated for the treatment of hypertension and falls under the Cardiovascular (CVS) therapeutic segment. The product has a market size of approximately $95 million for the twelve months ending September 2010 according to IMS and will be launched soon,” the company said in a release.
Hyderabad-based, Aurobindo Pharma now has a total of 138 ANDA approvals (108 final approvals and 30 tentative approvals) from USFDA.
Aurobindo Pharma Limited manufactures generic pharmaceuticals and active pharmaceutical ingredients.
